PCM Encore’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$313K Buy
5,425
+62
+1% +$3.56K 0.05% 317
2026
Q1
$325K Buy
5,363
+569
+12% +$33.2K 0.07% 290
2025
Q4
$259K Buy
+4,794
New +$231K 0.06% 342

Other funds holding BMY

PCM Encore's BMY Position: Q2 2026 in Review

PCM Encore increased its Bristol-Myers Squibb (BMY) stake by 1.2% in Q2 2026, buying an estimated $3.56K and bringing the position to 5,425 shares worth $313K. The position accounts for 0.05% of the portfolio, ranked #317.

PCM Encore first reported a position in BMY in Q4 2025 and has held it in 3 quarters since. The position peaked at $325K in Q1 2026. 2,513 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • PCM Encore held 5,425 shares of Bristol-Myers Squibb worth $313K as of Q2 2026.
  • PCM Encore bought 62 Bristol-Myers Squibb shares in Q2 2026, an estimated $3.56K.
  • Bristol-Myers Squibb made up 0.05% of PCM Encore's portfolio in Q2 2026, its #317 holding.
  • PCM Encore first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 3 quarters since.
  • PCM Encore's Bristol-Myers Squibb position peaked at $325K in Q1 2026.
  • 2,513 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on PCM Encore's 13F filing for Q2 2026, filed 11 Aug 2026.